FDA
-
-
-
-
-
-
-
Orchestra BioMed targets BACKBEAT trial completion by Q3 2026
-
-
-
-
-
-
-
Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
-
-
-
-
-
-
-
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Orchestra BioMed Inc. (OBIO) PT Lowered to $10 at H.C. Wainwright
-
-
-
-
-
-
-
Orchestra BioMed expands patient eligibility for hypertension study
-
-
-
-
-
-
-
Orchestra BioMed Announces Proposed Public Offering
-
-
-
-
-
-
-
Orchestra BioMed (OBIO) Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing Virtue SAB
-
328,603 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

